(Q24244031)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15846619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

0 references

1 reference

title

Olanzapine for schizophrenia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15846619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15846619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

author name string

L Duggan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15846619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

M Fenton

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15846619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

R Dardennes

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15846619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

A El-Dosoky

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15846619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

S Indran

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15846619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

publication date

18 April 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15846619%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

11 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15846619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

page(s)

CD001359

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15846619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15846619%20AND%20SRC:MED&resulttype=core&format=json

Is olanzapine better than haloperidol in resistant schizophrenia? A double-blind study in partial responders.

11 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Atypical antipsychotics and cognition in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

The Efficacy of High-Dose Olanzapine Versus Clozapine in Treatment-Resistant Schizophrenia: A Double-Blind Crossover Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Schizophrenia, VI: Treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Olanzapine vs haloperidol for treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Olanzapine versus haloperidol treatment in first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Sex differences in clinical response to olanzapine compared with haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double‐blind controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Olanzapine effects on auditory sensory gating in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

P300 and symptom improvement in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Olanzapine and improvement of tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Atypical antipsychotic drugs improve cognition in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Efficacy of clozapine in the treatment of atypical antipsychotic refractory schizophrenia: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Olanzapine: a novel atypical neuroleptic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

High-dose olanzapine for treatment-refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Using the proportional odds model to assess the relationship between a multi-item and a global item efficacy scale in a psychiatric clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Hyperglycemia in patients with schizophrenia who are treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Elevated prolactin in pediatric patients on typical and atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Negative symptoms in schizophrenia. Definition and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Bias in treatment assignment in controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Risperidone versus typical antipsychotic medication for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

The well-being of chronic mental patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Serotonergic basis of antipsychotic drug effects in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Dopamine receptors and the dopamine hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Quetiapine for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Chlorpromazine versus placebo for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Clozapine versus typical neuroleptic medication for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Cost Analysis of the Treatment of Schizophrenia in the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Delay in treating schizophrenia may narrow therapeutic window of opportunity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

A preliminary study of the comparative effects of olanzapine and fluphenazine on cognition in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Chlorpromazine versus placebo for schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

1 reference

7 January 2021

Doses of olanzapine, risperidone, and haloperidol in clinical practice: Results of a prospective pharmaco-epidemiological study (EFESO)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Differential olanzapine plasma concentrations by sex in a fixed-dose study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Adjunctive high-dose glycine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Health status assessment for the twenty-first century: item response theory, item banking and computer adaptive testing

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

1 reference

7 January 2021

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Treatment of suicidality in schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Winter workshop on schizophrenia, les diablerets, Switzerland, january 1994

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

The continued need for independent research on prescription drugs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Reducing the risk for suicide in schizophrenia and affective disorders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001359.PUB2

7 January 2021

10.1002/14651858.CD001359.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15846619%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference